Adaptimmune Therapeutics plc (ADAP) News

Adaptimmune Therapeutics plc (ADAP): $1.71

0.07 (+4.27%)

POWR Rating

Component Grades








Add ADAP to Watchlist
Sign Up

Industry: Biotech




#71 of 357

in industry

Filter ADAP News Items

ADAP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ADAP News Highlights

  • ADAP's 30 day story count now stands at 2.
  • Over the past 1 day, the trend for ADAP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG and MET are the most mentioned tickers in articles about ADAP.

Latest ADAP News From Around the Web

Below are the latest news stories about ADAPTIMMUNE THERAPEUTICS PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Key Insights Institutions' substantial holdings in Adaptimmune Therapeutics implies that they have significant...

Yahoo | December 7, 2023

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacyPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission o

Yahoo | December 6, 2023

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

Yahoo | November 30, 2023

Adaptimmune Receives Transfer of IND for Lete-cel Program

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, announces the transfer of the IND for letetresgene autoluecel

Yahoo | November 29, 2023

Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | November 13, 2023

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune’s Q3 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller. Please go ahead, Ms. Miller. Juli Miller: Good morning, and welcome to […]

Yahoo | November 13, 2023

Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically

Celebrations may be in order for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...

Yahoo | November 9, 2023

Adaptimmune Reports Third Quarter Financial Results and Business Update

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this yearSURPASS Phase 1 trial: 75% response rate in ovarian, urothelial, and head & neck cancers in patients with ≤ 3 prior lines of therapy (ESMO 2023)SURPASS trial plans: Phase 1 trial focused on head & neck and bladder cancers in earlier line treatment settings; Phase 2 SURPASS-3 ...

Yahoo | November 8, 2023

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen toolbox in developmentPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, provides a progress update on its PRAME program (ADP-600). Jo Brewer Adaptimmune Chief Scientific Officer: "We have taken everything we know about design a

Yahoo | November 8, 2023

Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.60, representing a +1.5% change from its previous close.

Yahoo | November 7, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!